News & Views

Join Telix at EANM 2023 to explore personalised diagnostics in urological cancers

Events, News,

Telix 2023 Half-Year Results: Revenue and Earnings Growth Marks Transition to a Sustainable Commercial-Stage Company

ASX, News,

Telix today announces its financial results for the half-year ended 30 June 2023. All figures are in AUD$ unless otherwise...

Telix Half-Year Results 2023 and Investor Call / Webcast Notification

ASX, News,

Telix today advises that it will release its financial results for the half-year ended 30 June 2023 on Wednesday 23 August...

First Patient Dosed in Pivotal Phase III Study of TLX591-CDx (Illuccix®) for Prostate Cancer Imaging in Chinese Patients

Clinical, News,

Telix today announces that a first patient has been dosed in China in the pivotal Phase III registration study of TLX591-CDx (Illuccix®, Kit for the preparation of 68Ga-PSMA-11), for the...

First Patient Dosed in IPAX-2 Study of TLX101 Brain Cancer Therapy Candidate in Patients with Newly Diagnosed Glioblastoma

Clinical, News,

Telix today announces that a first patient has been dosed in a Phase I study of the Company’s investigational therapy TLX101 (4-L-[131I] iodo-phenylalanine, or 131I-IPA) in combination with post-surgical standard...

Telix Reports Continued Double-Digit Revenue Growth and Positive Operating Cash Flow

ASX, News,

Telix today issues its Appendix 4C quarterly cash flow report and accompanying Activities Report for the quarter ended 30 June 2023 (Q2 2023). All figures are in AUD$ unless otherwise...

First Patient Dosed in STARSTRUCK Study

Clinical, News,

Telix today announces that the first patient has been dosed in a Phase I study of the Company’s investigational targeted radiation therapy, TLX250, in combination with a Merck KGaA, Darmstadt,...

Telix Quarterly Results and Investor Call / Webcast Notification

ASX, News,

Telix today advises it will release its Appendix 4C Quarterly Cash Flow Report and Activities Report for the period ended 30 June 2023 on Wednesday 19 July 2023 at market...

New ZIRCON Phase III Data Presented at SNMMI: Potential Utility of TLX250-CDx in Staging and Monitoring ccRCC

Clinical, Events, News,

today announces further details of the positive results from its completed pivotal Phase III ZIRCON study of TLX250-CDx (89Zr-DFO-girentuximab) in clear cell renal cell carcinoma (ccRCC) (ClinicalTrials.gov Identifier:...